CAMK2G and myocardial infarction: Despite several studies having demonstrated the cardioprotective effects of various types of CaMKII inhibitors in preclinical studies, NP2O2, which is a CaMKII-δ inhibitor, failed to improve cardiac performance in post-MI patients.